World’s 1st Healthcare Metaverse from DeHealth

A British non-profit organization, DeHealth, is revolutionizing the healthcare industry. The company announced the start of the creation of a Decentralized Metaverse, which will take millions of doctors and patients to a new world where they can work, interact with each other in full 3D format and earn virtual assets by selling their anonymized medical data.

The HLT (health) token will become the main mean of settlement within the ecosystem that will power it from the inside.

The DeHealth Metaverse will be an extension of the VR, AR, and Mixed Reality (MR) technologies. It will allow several participants, for instance, a doctor and a patient, to communicate via one virtual space, assimilating the real-world situation.

The user’s ability to transfer their digital identity (avatar), including all medical data collected through other digital platforms, into the new virtual world without problems will be critical to the success of the DeHealth metaverse.

Anna Bondarenko, the Co-Founder DeHealth commented: “Our goal is to provide people with the most advanced technologies to preserve their health so that every person in the world, regardless of the place of residence, social status, and financial capabilities, can control their health and life. The future of healthcare lies not in treatment but the prevention of diseases. Our AI will notice the slightest deviations from the human norm and warn about it. Thanks to HLT, each person in the metaverse can sell their impersonal medical information with their own hands.”

Denys Tsvaig, the Co-Founder of DeHealth, commented: “To implement our metaverse, we will use a new technological stack: the Hospital OS digital platform, the blockchain network (cryptoeconomics of the HLT Network), fundamentally different AR / VR devices, electronic clothing, 5G communication networks, quantum computing & communications, cybersecurity, data storage chips using synthetic biology and so much more. The metaverse may require a new programming model that resembles a living and open developing platform, where millions of users seamlessly move from one world to another using the avatar of themselves.”

The DeHealth metaverse will be supported by a wide range of devices – from smartphones and PCs to mixed types of headsets.

Holders of HTL tokens will become the first investors and leaders of the new trend in healthcare.

A preliminary version of the metaverse will be available in late 2022. It will open up access to 3 million Hospital OS users, DeHealth said.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.